- In this section:
- AmoyDx BRCA Pro Panel user manual
The BRCA Pro Panel offers a comprehensive genetic test that detects BRCA1/2 mutations and variants that could predispose individuals to breast and ovarian cancer. It supports early diagnosis and genetic counselling by identifying individuals who are at high risk, allowing for better preventive measures and more tailored treatment strategies. The panel helps clinicians provide personalised care for patients, offering options like preventive surgeries, chemoprevention, or targeted therapies based on the genetic findings.
Benefits of the AmoyDx BRCA Pro Panel
- Comprehensive BRCA1/2 mutation detection - identifies SNVs, indels, and large rearrangements (LRs) across all coding regions, intron/exon boundaries, and select UTRs for high-precision variant analysis
- Supports hereditary and somatic cancer risk assessment - detects both germline and somatic mutations in breast, ovarian, prostate, pancreatic, and melanoma cancers, aiding in early diagnosis and targeted therapy decisions
- High sensitivity and accuracy - leverages AmoyDx HANDLE® technology with unique molecular indexes (UMIs) to eliminate sequencing bias and improve variant detection reliability
- Fast and cost-effective workflow – NGS library preparation in under 5 hours, with only 1 hour of hands-on time, making it a time-saving, decentralised solution for laboratories
- Secure and streamlined data analysis - integrates seamlessly with AmoyDx NGS Data Analysis System (ANDAS) for automated, secure, and intuitive mutation analysis while ensuring data protection and regulatory compliance
Applications of the AmoyDx BRCA Pro Panel
- Detection of BRCA1/2 germline and somatic mutations
- Risk assessment for hereditary breast, ovarian, prostate, and pancreatic cancers
- Determining eligibility for PARP inhibitors (PARPi) and other targeted therapies
- Clinical decision-making for cancer prevention and treatment
- Genetic screening in oncology and molecular pathology labs
Specifications
Target regions | All coding regions of BRCA1/2 genes, exon-intron boundaries, some introns and UTRs |
---|---|
Alterations detected | SNVs & InDels (somatic/germline), LRs (germline) |
Sample type | DNA from FFPE tissue, whole blood |
DNA input | Optimal 50ng (minimum 30ng) |
Data output per sample | 0.06 Gb for germline variants, 0.3 Gb for somatic variants |
Sequencing type | PE150 |
Sequencer | Illumina MiSeqDx, NextSeq 500, NextSeq 550Dx |
TAT for library preparation | 5 hours (<1 hour hands-on time) |
TAT from sample to report | 3 days |
Materials for download
AmoyDx BRCA Pro Panel user manual
Products
Note: product availability depends on country - see product detail page.
Details | Cat number & supplier | Size | Price |
BRCA Pro Panel 8.06.0104 · Amoy Diagnostics | 8.06.0104 Amoy Diagnostics |
24 tests |
£4542.00
24 tests
view
|
BRCA Pro Panel 8.06.0117 · Amoy Diagnostics | 8.06.0117 Amoy Diagnostics |
24 tests |
£4542.00
24 tests
view
|